Drawipas
Drawipas Brand names, Drawipas Analogs
- Apl-Luster
- Arbotect
- Bioguard
- Bovizole
- Chemviron TK 100
- Cropasal
- Drawipas
- Eprofil
- Equivet TZ
- Equizole
- Hokustar hp
- Hymush
- Lombristop
- Mertec
- Mertect
- Mertect 160
- Mertect 340f
- Mertect lsp
- Metasol TK 100
- Metasol TK 10
- Mintesol
- Mintezol
- Minzolum
- Mycozol
- Nemacin
- Nemapan
- Omnizole
- Ormogal
- Polival
- RPH
- Sanaizol 100
- Sistesan
- Storite
- TBZ 6
- TBZ 60W
- TBDZ
- TBZ
- Tebuzate
- Tecto
- Tecto 10P
- Tecto 40F
- Tecto 60
- Tecto B
- Tecto rph
- Testo
- Thiaben
- Thiabendazol
- Thiabendole
- Thiabenzazole
- Thiabenzole
- Thibendole
- Thibenzol
- Thibenzole
- Thibenzole 200
- Thibenzole att
- Thiprazole
- Tiabenda
- Tiabendazol
- Tiabendazole
- Tibimix 20
- Tobaz
- Top form wormer
- Triasox
- Tubazole
Drawipas Brand Names Mixture
- No information avaliable
Drawipas Chemical_Formula
C11H16N2O
Drawipas RX_link
http://www.rxlist.com/cgi/generic3/tocainide.htm
Drawipas fda sheet
Drawipas msds (material safety sheet)
Drawipas Synthesis Reference
No information avaliable
Drawipas Molecular Weight
192.258 g/mol
Drawipas Melting Point
246-266 oC
Drawipas H2O Solubility
1.07E+004 mg/L
Drawipas State
Solid
Drawipas LogP
1.308
Drawipas Dosage Forms
400 mg and 600 mg tablets for oral administration
Drawipas Indication
For the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening.
Drawipas Pharmacology
Tocainide is a primary amine analog of lidocaine with antiarrhythmic properties useful in the treatment of ventricular arrhythmias. Tocainide, like lidocaine, produces dose dependent decreases in sodium and potassium conductance, thereby decreasing the excitability of myocardial cells. In experimental animal models, the dose-related depression of sodium current is more pronounced in ischemic tissue than in normal tissue. Tocainide is a Class I antiarrhythmic compound with electrophysiologic properties in man similar to those of lidocaine, but dissimilar from quinidine, procainamide, and disopyramide.
Drawipas Absorption
Following oral administration, the bioavailability approaches 100 percent, and is unaffected by food.
Drawipas side effects and Toxicity
The oral LD50 of tocainide was calculated to be about 800 mg/kg in mice, 1000 mg/kg in rats, and 230 mg/kg in guinea pigs; deaths were usually preceded by convulsions.
Drawipas Patient Information
Drawipas Organisms Affected
Humans and other mammals
